Cell immunotherapy for prevention, recurrence, and metastasis of liver cancer

Share This Post

The incidence of liver cancer in China is very high, because liver cancer is difficult to find in the early stage of the disease. Once the diagnosis is often in the middle and late stages, the optimal treatment time is often missed. The traditional treatment for liver cancer is surgery, radiotherapy and chemotherapy, etc. However, such treatment methods generally have a relatively high recurrence rate, and the survival rate of patients is relatively low. To prevent recurrence and metastasis of liver tumors, cell immunotherapy can be tried at this time.

 

Due to the limitation of liver tumor size, growth location, and relationship with the position of large blood vessels and biliary tract, some patients with special small liver cancer, huge liver tumor, and middle-advanced liver cancer with multiple metastatic lesions often lose the opportunity for surgery.

However, for these patients, the expert’s approach is to first use argon-helium ultra-cold knife minimally invasive treatment, through physical freezing and thawing to destroy the cell structure of tumor tissue in a short period of time, promote tumor tissue necrosis and close tumor small blood vessels. At the same time, combined with interventional therapy, embolization of tumor large vessels and local high-concentration chemotherapy, the combination of the two therapies can inhibit the growth of liver cancer cells and eliminate tumor lesions in a short period of time.

In general, most of the primary liver cancers are large undetectable liver cancers, which are accompanied by tumor thrombi in the internal and external portal vein system. The recurrence rate within one year after radiotherapy and chemotherapy is as high as 60%, and the 3-year survival rate is less than 30%. Therefore, the most important thing for liver cancer surgery is to prevent recurrence, but traditional radiotherapy and chemotherapy have large side effects, which can easily lead to liver cirrhosis and even liver function damage.

A relatively new treatment method-biological cell immunity

(CIK cells) have a significant effect on advanced liver cancer. This therapy can help clear the remaining cancer cells in the patient’s body, restore the patient’s immune function of identifying and killing cancer cells, and thus prevent and control tumor metastasis.

CIK cells are cytokine-induced killer cells, which are mononuclear cells isolated from peripheral blood, bone marrow or umbilical cord blood. After a certain period of time in the laboratory, they are induced, proliferated, and then reinfused into the patient to directly kill the blood, Tumor cells in the lymph also regulate and enhance the patient’s immune function.

According to clinical statistics, 9 patients with stage 4 liver cancer undergo more than 3 cycles of cell immunotherapy after surgery, which can better prevent recurrence of liver cancer after surgery. The average survival time after treatment is 20 months, and the recurrence rate within 1 year is only 22.2%, and the discomfort symptoms of most patients are improved

The above simple understanding of preventing liver tumor recurrence and metastasis, you can try cell immunotherapy, cell immunotherapy is a relatively new method of treating cancer, such as biological cell immunotherapy, can help patients remove residual cancer cells in the body, in addition to immunity Therapy has the effect of identifying and killing cancer cells, thereby further preventing the spread and metastasis of tumors.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy